{
  "docId": "019dd923-5f69-752d-a9b8-7335d4e4bbbd",
  "docSlug": "UazyKuUCi7yVVPL3wJds",
  "documentTitle": "See the pitch deck that Compass Pathways used to raise $80 million and fuel its rise into one of the world's biggest psychedelics companies",
  "authorId": "Pitchdecks",
  "authorName": "Compass Pathways",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 16,
  "pageCount": 28,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 40,
  "notes": "The table highlights Psilocybin's potential competitive advantage in therapy duration and efficacy compared to traditional and emerging treatments.",
  "elementsJson": [
    "action_title",
    "comparison_table",
    "callout_box",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b8-7335d4e4bbbd/16",
  "deckHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.2,
        "y": 0.82
      },
      "kind": "callout",
      "text": "Mission: Ubiquitous access for as many patients as possible",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c12ec2e-f0fd-41fc-a79b-434ad943b0f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Medical Journals; Company websites; Expert interviews; BTIG Analyst Report (2017); Oanda.com",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6c93feb-d1f2-4266-bcfc-33dca5c3df3c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "1. For TRD patient population... 4. Atypical Antipsychotic (based on 1 year of treatment...)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1032c14-c6c0-4feb-b733-ba55ff5aa32a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "table",
      "text": "Comparison table of TRD treatments across Stage in Treatment Pathway, Efficacy level, Episode Therapy Regime, Reimbursement level, and Total Cost.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "117bc3c0-d0b4-4c9a-824f-f7b1247d9c55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Competition: Psilocybin likely more efficacious, more affordable, and with shorter therapy regime than alternatives for TRD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f9165e37-ff66-41fa-876a-f3452bb9d5b5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_table",
      "slug": null,
      "matchId": "a6096bdc-aa0a-45c9-8e96-58932a083e53",
      "evidence": "Structured data comparison of competitive landscape",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 17,
      "from": 10,
      "beatId": "1b24f627-5397-46d5-a3ed-637425948073",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 10 through 17 present psilocybin therapy as a solution, detailing its value proposition, development program, and market potential.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}